FGP
RAPP

Freestone Grove Partners’s Rapport Therapeutics RAPP Stock Holding History

Freestone Grove Partners’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4M Buy
+127,783
New +$3.59M 0.03% 337
2025
Q4 		– Sell
-45,130
Closed -$1.34M – 984
2025
Q3 		$1.34M Buy
+45,130
New +$805K 0.01% 407

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Freestone Grove Partners's RAPP Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Rapport Therapeutics (RAPP) in Q1 2026: 127,783 shares worth $4M. The stake represents 0.03% of the portfolio and ranks #337 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in RAPP as recently as Q3 2025.

Freestone Grove Partners first reported a position in RAPP in Q3 2025 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Freestone Grove Partners held 127,783 shares of Rapport Therapeutics worth $4M as of Q1 2026.
  • Rapport Therapeutics was a new Freestone Grove Partners position in Q1 2026.
  • Rapport Therapeutics made up 0.03% of Freestone Grove Partners's portfolio in Q1 2026, its #337 holding.
  • Freestone Grove Partners first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.